Immunogenicity of therapeutics: a matter of efficacy and safety

Are neutralizing anti-GM-CSF autoantibodies present in all healthy persons?

(2010) A. Meager et al.   BLOOD

Optimization algorithms for functional deimmunization of therapeutic proteins

(2010) Andrew S Parker et al.   BMC BIOINFORMATICS

Parameters for establishing humanized mouse models to study human immunity: Analysis of human hematopoietic stem cell engraftment in three immunodeficient strains of mice bearing the IL2rγnull mutation

(2010) Michael A. Brehm et al.   CLINICAL IMMUNOLOGY

Protein aggregation—Pathways and influencing factors

(2010) Wei Wang et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Immunological substance testing on human lymphatic micro-organoids in vitro

(2010) Christoph Giese et al.   JOURNAL OF BIOTECHNOLOGY

Clinical concerns of immunogenicity produced at cellular levels by biopharmaceuticals following their parenteral administration into human body

(2010) Shunmugaperumal Tamilvanan et al.   JOURNAL OF DRUG TARGETING

The immunogenicity of humanized and fully human antibodies

(2010) Fiona A. Harding et al.   mAbs

PEG conjugates in clinical development or use as anticancer agents: An overview

(2009) Gianfranco Pasut et al.   ADVANCED DRUG DELIVERY REVIEWS

A Novel Reduced Immunogenicity Bispecific Targeted Toxin Simultaneously Recognizing Human Epidermal Growth Factor and Interleukin-4 Receptors in a Mouse Model of Metastatic Breast Carcinoma

(2009) S. Oh et al.   CLINICAL CANCER RESEARCH

Reducing risk, improving outcomes: Bioengineering less immunogenic protein therapeutics

(2009) Anne S. De Groot et al.   CLINICAL IMMUNOLOGY

Reducing the Immunogenicity of Protein Therapeutics

(2009) Masanori Onda   CURRENT DRUG TARGETS

Recommendations regarding technical standards for follow-on biologics: comparability, similarity, interchangeability

(2009) Gregory C. Davis et al.   CURRENT MEDICAL RESEARCH AND OPINION

HAHA – nothing to laugh about. Measuring the immunogenicity (human anti-human antibody response) induced by humanized monoclonal antibodies applying ELISA and SPR technology

(2009) Andreas Nechansky   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Immunogenicity of aggregates of recombinant human growth hormone in mouse models

(2009) Amber Haynes Fradkin et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Implications of neutralising antibodies on therapeutic efficacy

(2009) Antonio Bertolotto   JOURNAL OF THE NEUROLOGICAL SCIENCES

Immunological mechanism underlying the immune response to recombinant human protein therapeutics

(2009) Melody Sauerborn et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Effects of Shielding Adenoviral Vectors with Polyethylene Glycol on Vector-Specific and Vaccine-Mediated Immune Responses

(2008) Eric A. Weaver et al.   HUMAN GENE THERAPY

Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products

(2008) Eugen Koren et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Effects of glycosylation on the stability of protein pharmaceuticals

(2008) Ricardo J. Solá et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

A machine-learning approach for predicting B-cell epitopes

(2008) Nimrod D. Rubinstein et al.   MOLECULAR IMMUNOLOGY

Protein therapeutics: a summary and pharmacological classification

(2007) Benjamin Leader et al.   NATURE REVIEWS DRUG DISCOVERY